Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the drug octreotide acetate in a new intranasal
formulation and compare it to the FDA-approved subcutaneous (SC) injection formulation. The
two octreotide acetate formulations will be evaluated following separate administrations for
safety and tolerability including any side effects, the speed at which the drug is absorbed
and eliminated in the body, and the ability of the drug to lower the levels of growth hormone
(GH) and insulin-like growth factor 1 (IGF-1).